Biovica International AB Class B

As of July 31, 2026, Biovica International AB Class B carries a market capitalization of 145.96M, placing it among publicly traded companies globally. Its enterprise value stands at 100.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biovica International AB Class B's next confirmed earnings release is scheduled for December 17, 2026.

As of July 31, 2026, Biovica International AB Class B has 291.91M shares outstanding.

These figures are as of July 31, 2026. The price-to-sales ratio is 9.57, and the price-to-book ratio stands at 2.19.

These figures are as of July 31, 2026. The EV/Sales ratio of 6.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 100.39M versus a market cap of 145.96M, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, Biovica International AB Class B maintains a current ratio of 3.06, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.05, indicating elevated leverage, while an interest coverage ratio of -219.02 demonstrates limited ability to service its debt obligations.

Over the twelve months ended July 31, 2026, Biovica International AB Class B posted a negative return on equity (ROE) of -156.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -98.35, reflecting losses generated across the asset base. The company generates approximately 593,080.00 in revenue per employee across its workforce of 25.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.26 indicates how many times Biovica International AB Class B sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended July 31, 2026, Biovica International AB Class B recorded 1.57M in income tax expense. The company reported a pretax loss of -70.66M and -72.23M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Biovica International AB Class B's stock has declined approximately 46.85% over the past 52 weeks. The 50-day moving average sits at 0.36, while the 200-day moving average is 0.38.

Over the twelve months ended July 31, 2026, Biovica International AB Class B generated 14.83M in revenue and converted that into -72.23M in net income, yielding earnings per share of -0.25. EBITDA reached -63.30M, while operating income came in at -71.65M.

As of July 31, 2026, Biovica International AB Class B holds 51.59M in cash and equivalents against 6.02M in total debt, resulting in a net debt position of -51.59M. Total book value stands at 66.57M, with working capital of 40.43M providing operational flexibility.

Biovica International AB Class B produced -61.71M in operating cash flow over the twelve months ended July 31, 2026. After subtracting -2.32M in capital expenditures, free cash flow totaled -64.04M - equivalent to -0.23 per share.

Over the twelve months ended July 31, 2026, Biovica International AB Class B posted a gross margin of 96.85, reflecting its pricing power and cost economics. The operating margin of -483.21 and net profit margin of -487.17 provide insight into operational efficiency.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -45.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -68.11, meaning Biovica International AB Class B raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Biovica International AB Class B's most recent stock split took place on July 15, 2025 with a 846:917 split ratio.

As of July 31, 2026, Biovica International AB Class B has an Altman Z-Score of -11.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.